MSI-H CRC
Oncology · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab First-line treatment of microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC). | Jul 2025 | Not recommended | 8 individuals Rare Cancers Australia · Bowel Cancer Australia · Medical Oncology Group Australia |
Who spoke
Rare Cancers Australia · Bowel Cancer Australia · Medical Oncology Group Australia
What the PBS pays
$199M in government benefit over 2024–25, across 11,929 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| nivolumab; ipilimumab | $199M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.